Rezolute, a clinical stage biopharmaceutical company, entered into a $30 million debt financing agreement with investment affiliates managed by SLR Capital Partners.
Upon closing, $15 million of the $30 million loan was funded with an interest-only period of 24 months. The remaining $15 million may be funded when Rezolute achieves certain predetermined milestones and conditions.
“The access to capital provided by this facility gives Rezolute non-dilutive operational flexibility as we continue advancing our pipeline. Thanks to Armentum Partners in their brokering of this competitive deal for Rezolute,” Nevan Elam, CEO of Rezolute, said.
